Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Common Equity (2019 - 2025)

Immunocore Holdings' Common Equity history spans 4 years, with the latest figure at $381.0 million for Q4 2025.

  • For Q4 2025, Common Equity rose 5.63% year-over-year to $381.0 million; the TTM value through Dec 2025 reached $381.0 million, up 5.63%, while the annual FY2025 figure was $381.0 million, 5.63% up from the prior year.
  • Common Equity for Q4 2025 was $381.0 million at Immunocore Holdings, down from $396.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $396.6 million in Q3 2025 and bottomed at $338.9 million in Q4 2022.
  • The 4-year median for Common Equity is $360.7 million (2024), against an average of $366.0 million.
  • The largest annual shift saw Common Equity grew 8.83% in 2023 before it fell 2.2% in 2024.
  • A 4-year view of Common Equity shows it stood at $338.9 million in 2022, then grew by 8.83% to $368.8 million in 2023, then dropped by 2.2% to $360.7 million in 2024, then increased by 5.63% to $381.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Common Equity are $381.0 million (Q4 2025), $396.6 million (Q3 2025), and $388.5 million (Q2 2025).